Editor’s Choice – The Journal of Urology® March 2025
Thursday, May 8th, 2025
We are proud to announce that the recent clinical study titled “Uromonitor: Clinical Validation and Performance Assessment of a Urinary Biomarker Within the Surveillance of Patients With Nonmuscle-Invasive Bladder Cancer”, led by Dr. Pedro Ramos et al., has been selected as Editor’s Choice in the March 2025 edition of The Journal of Urology®.
This prestigious recognition places Uromonitor® at the forefront of innovation in bladder cancer diagnostics, reinforcing its role as a transformative tool for the non-invasive surveillance of nonmuscle-invasive bladder cancer (NMIBC).
Key Insight from the Editors:
“These thought-fully constructed studies not only aim to demonstrate clinical utility but also address the real-world challenges of managing patients with urothelial cancer, offering practical solutions to improve patient out-comes and ease the burden on health care systems. This strong work continues in this issue of The Journal of Urology. First up is a paper from Ramos et al. from Portugal evaluating the performance of Uromonitor as a urine biomarker for nonmuscle-invasive bladder cancer (NMIBC). The team focus the intervention as a potential alternative to current standard of care for detecting recurrence during routine follow-up. Uromonitor demonstrated high sensitivity (87%), specificity (99%), positive predictive value (93%), and negative predictive value (99%) compared with gold-standard cystoscopic surveillance. Notably, Uromonitor exhibited fewer false positives than cystoscopy as well as reliability across all grades and stages. The authors conclude that the results support its clinical utility and potential to improve NMIBC surveillance practices.” Editors’ Choice | Journal of Urology
